Mihaela Mates
Queen's University · 86 works · 1,979 citations · h-index 22
Top works
- First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
- The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
- Hepatitis B and C virus infection in Romanian non‐Hodgkin's lymphoma patients
- Optimal Systemic Therapy for Early Breast Cancer in Women: A Clinical Practice Guideline
- A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
- Emergency Room Visits and Hospital Admission Rates After Curative Chemotherapy for Breast Cancer
- A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
- Adjuvant Chemotherapy for Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline
- Adjuvant Endocrine Therapy for Early Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline
- A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer
- A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting
- Real-World Impact of Granulocyte-Colony Stimulating Factor on Febrile Neutropenia
- Systemic Targeted Therapy for her2-Positive Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline
- Improving Timeliness of Oncology Assessment and Cancer Treatment Through Implementation of a Multidisciplinary Lung Cancer Clinic
- Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)
- A Case of Successful Pembrolizumab Rechallenge in a Patient with Non-Small-Cell Lung Cancer and Grade 3 Dermatomyositis
- Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature
- A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
- Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy